5.15 USD
+0.12 (+2.39%)
At close: Feb 6, 2026
5.15 USD
0 (0%)
After Hours: 2/6/2026, 8:00:00 PM
We assign a fundamental rating of 5 out of 10 to MDXG. MDXG was compared to 523 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MDXG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- MDXG had positive earnings in the past year.
- In the past year MDXG had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
- In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
- MDXG has a better Return On Assets (12.80%) than 94.48% of its industry peers.
- Looking at the Return On Equity, with a value of 17.09%, MDXG belongs to the top of the industry, outperforming 95.05% of the companies in the same industry.
- MDXG has a better Return On Invested Capital (15.15%) than 95.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MDXG's Profit Margin of 10.38% is amongst the best of the industry. MDXG outperforms 91.43% of its industry peers.
- The Operating Margin of MDXG (13.73%) is better than 92.95% of its industry peers.
- In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
- MDXG has a Gross Margin of 81.99%. This is amongst the best in the industry. MDXG outperforms 85.71% of its industry peers.
- In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
- Compared to 1 year ago, MDXG has more shares outstanding
- MDXG has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
- MDXG has an Altman-Z score of 7.99. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
- With a decent Altman-Z score value of 7.99, MDXG is doing good in the industry, outperforming 79.05% of the companies in the same industry.
- The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of MDXG (0.27) is better than 95.43% of its industry peers.
- MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
- MDXG's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. MDXG is outperformed by 60.76% of its industry peers.
- Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 7.99 |
ROIC/WACC1.74
WACC8.73%
2.3 Liquidity
- A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
- The Current ratio of MDXG (4.41) is comparable to the rest of the industry.
- MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- MDXG's Quick ratio of 3.95 is in line compared to the rest of the industry. MDXG outperforms 49.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
- The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
- The Revenue has grown by 14.77% in the past year. This is quite good.
- The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
- Based on estimates for the next years, MDXG will show a decrease in Earnings Per Share. The EPS will decrease by -5.49% on average per year.
- Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 14.49% on average per year.
EPS Next Y16.07%
EPS Next 2Y-37.8%
EPS Next 3Y-5.49%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y7.11%
Revenue Next 3Y9.76%
Revenue Next 5Y14.49%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- MDXG is valuated correctly with a Price/Earnings ratio of 14.31.
- Based on the Price/Earnings ratio, MDXG is valued cheaper than 96.57% of the companies in the same industry.
- MDXG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.93.
- The Price/Forward Earnings ratio is 45.90, which means the current valuation is very expensive for MDXG.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 90.67% of the companies listed in the same industry.
- MDXG's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 45.9 |
4.2 Price Multiples
- MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 97.71% of the companies in the same industry.
- 98.29% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.42 | ||
| EV/EBITDA | 9.31 |
4.3 Compensation for Growth
- MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MDXG has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as MDXG's earnings are expected to decrease with -5.49% in the coming years.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y-37.8%
EPS Next 3Y-5.49%
5. Dividend
5.1 Amount
- No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.15
+0.12 (+2.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners71.94%
Inst Owner Change-0.61%
Ins Owners1.79%
Ins Owner Change-0.11%
Market Cap762.72M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target10.61 (106.02%)
Short Float %4.36%
Short Ratio7.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)-14.75%
PT rev (3m)-14.75%
EPS NQ rev (1m)-30.16%
EPS NQ rev (3m)-15.39%
EPS NY rev (1m)-21.43%
EPS NY rev (3m)1.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 45.9 | ||
| P/S | 1.94 | ||
| P/FCF | 11.42 | ||
| P/OCF | 11.24 | ||
| P/B | 3.19 | ||
| P/tB | 3.66 | ||
| EV/EBITDA | 9.31 |
EPS(TTM)0.36
EY6.99%
EPS(NY)0.11
Fwd EY2.18%
FCF(TTM)0.45
FCFY8.76%
OCF(TTM)0.46
OCFY8.89%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.89
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 7.99 |
F-Score6
WACC8.73%
ROIC/WACC1.74
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y16.07%
EPS Next 2Y-37.8%
EPS Next 3Y-5.49%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y7.11%
Revenue Next 3Y9.76%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y18.36%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.
What is the earnings growth outlook for MIMEDX GROUP INC?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to grow by 16.07% in the next year.